Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
Soundararajan Krishnaswamy,Rajani Kanteti,Jonathan S. Duke-Cohan,Sivakumar Loganathan,Wanqing Liu,Patrick C. Ma,Martin Sattler,Patrick A. Singleton,Nithya Ramnath,Federico Innocenti,Dan L. Nicolae,Zheng Ouyang,Jie Liang,John D. Minna,Mark Kozloff,Mark K. Ferguson,Viswanathan Natarajan,Yi Ching Wang,Joe G.N. Garcia,Everett E. Vokes,Ravi Salgia +20 more
Reads0
Chats0
TLDR
The most frequent mutation of MET, MET-N375S, seems to confer resistance to MET inhibition based on hepatocyte growth factor ligand binding, molecular modeling, and apoptotic susceptibility to MET inhibitor studies.Abstract:
Purpose: African Americans have higher incidence and poorer response to lung cancer treatment compared with Caucasians. However, the underlying molecular mechanisms for the significant ethnic difference are not known. The present study examines the ethnic differences in the type and frequency of MET proto-oncogene (MET) mutation in lung cancer and correlated them with other frequently mutated genes such as epidermal growth factor receptor (EGFR), KRAS2, and TP53. Experimental Design: Using tumor tissue genomic DNA from 141 Asian, 76 Caucasian, and 66 African American lung cancer patients, exons coding for MET and EGFR were PCR amplified, and mutations were detected by sequencing. Mutation carriers were further screened for KRAS2 and TP53 mutations. Functional implications of important MET mutations were explored by molecular modeling and hepatocyte growth factor binding studies. Results: Unlike the frequently encountered somatic mutations in EGFR, MET mutations in lung tumors were germline. MET-N375S, the most frequent mutation of MET, occurred in 13% of East Asians compared with none in African Americans. The frequency of MET mutations was highest among male smokers and squamous cell carcinoma. The MET-N375S mutation seems to confer resistance to MET inhibition based on hepatocyte growth factor ligand binding, molecular modeling, and apoptotic susceptibility to MET inhibitor studies. Conclusions: MET in lung cancer tissues contained nonsynonymous mutations in the semaphorin and juxtamembrane domains but not in the tyrosine kinase domain. All the MET mutations were germline. East Asians, African-Americans, and Caucasians had different MET genotypes and haplotypes. MET mutations in the semaphorin domain affected ligand binding. (Clin Cancer Res 2009;15(18):5714–23)read more
Citations
More filters
Journal ArticleDOI
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik,Paul K. Paik,Alexander Drilon,Alexander Drilon,Pang Dian Fan,Helena A. Yu,Helena A. Yu,Natasha Rekhtman,Michelle S. Ginsberg,Laetitia Borsu,Nikolaus Schultz,Michael F. Berger,Charles M. Rudin,Charles M. Rudin,Marc Ladanyi +14 more
TL;DR: Responses to the MET inhibitors crizotinib and cabozantinib in patients with lung adenocarcinomas harboring MET exon 14 splice site mutations are reported, identifying a new potential therapeutic target in this disease.
Journal ArticleDOI
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
TL;DR: The biology and clinical significance behind MET proto‐oncogene receptor tyrosine kinase (MET) exon 14 alterations andMET amplification in NSCLC are explored, the role of MET amplification in the setting of acquired resistance to EGFR tyrosINE kinase inhibitor therapy in EGFR‐mutant NSCLCs is explored, and the history of MET pathway inhibitor drug development inNSCLC is highlighted.
Journal ArticleDOI
Molecular pathways and therapeutic targets in lung cancer
Emma Shtivelman,Thomas A. Hensing,George R. Simon,Phillip A. Dennis,Gregory A. Otterson,Raphael Bueno,Ravi Salgia +6 more
TL;DR: The approved and investigational targeted therapies as well as the immune therapies, and clinical trials exploring the variety of targeted approaches to treatment of lung cancer are the main focus of this review.
Journal Article
EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.
TL;DR: The major mechanisms of acquired resistance to EGFR-TKIs are summarized, the development of rationally designed molecular target drugs in accordance with each mechanism is discussed, in the hope of shedding light on the great achievements obtained and tough obstacles the authors have to overcome in the battle against this deadly disease.
Journal ArticleDOI
The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.
TL;DR: Research in Met prognostics and predictors of drug response is now shifting toward more sophisticated methodologies suitable for development as validated and effective biomarkers that can be partnered with therapeutics to improve patient survival.
References
More filters
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Journal ArticleDOI
A new statistical method for haplotype reconstruction from population data.
TL;DR: A new statistical method is presented, applicable to genotype data at linked loci from a population sample, that improves substantially on current algorithms and performs well in absolute terms, suggesting that reconstructing haplotypes experimentally or by genotyping additional family members may be an inefficient use of resources.
Journal ArticleDOI
Cancer statistics, 2007.
TL;DR: While the absolute number of cancer deaths decreased for the second consecutive year in the United States, much progress has been made in reducing mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years.
Journal ArticleDOI
The phosphoinositide 3-kinase pathway.
TL;DR: The PI3K pathway is implicated in human diseases including diabetes and cancer, and understanding the intricacies of this pathway may provide new avenues for therapuetic intervention.
Related Papers (5)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman,Kreshnik Zejnullahu,Tetsuya Mitsudomi,Youngchul Song,Courtney Hyland,Joon Oh Park,Neal I. Lindeman,Christopher-Michael Gale,Xiaojun Zhao,James J. Christensen,Takayuki Kosaka,Alison J. Holmes,Andrew M. Rogers,Federico Cappuzzo,Tony Mok,Charles Lee,Bruce E. Johnson,Lewis C. Cantley,Pasi A. Jänne +18 more
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Jonathan F. Bean,Cameron Brennan,Jin-Yuan Shih,Gregory J. Riely,Gregory J. Riely,Agnes Viale,Lu Wang,Dhananjay Chitale,Noriko Motoi,Noriko Motoi,Janos Szoke,Stephen Broderick,Marissa Balak,Wen Cheng Chang,Chong-Jen Yu,Adi F. Gazdar,Harvey I. Pass,Valerie W. Rusch,William L. Gerald,Shiu Feng Huang,Pan-Chyr Yang,Vincent Miller,Vincent Miller,Marc Ladanyi,Chih-Hsin Yang,William Pao,William Pao +26 more
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
Laura S. Schmidt,Fuh Mei Duh,F. Chen,Takeshi Kishida,Gladys Glenn,Peter L. Choyke,Stephen W. Scherer,Zhengping Zhuang,Irina A. Lubensky,Michael Dean,Rando Allikmets,Abirami Chidambaram,Ulf S.R. Bergerheim,J. T. Feltis,C. Casadevall,A. Zamarron,M. Bernues,Stéphane Richard,C. J. M. Lips,McClellan M. Walther,Lap-Chee Tsui,Laura Geil,Mary Lou Orcutt,Thomas Stackhouse,J. Lipan,L. Slife,Hiltrud Brauch,Jochen Decker,G. Niehans,M. D. Hughson,Holger Moch,Stefan Storkel,Michael I. Lerman,W.M. Linehan,B. Zbar +34 more
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more